GlassScriptPhysician profile
Haoran Yu
NPI 1528174547
$12,083.12
in general payments reported to CMS, 2019-2025
55 companies · $1,791 in 2025
The $1,791 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,712 · 2020: $1,832 · 2021: $1,833 · 2022: $1,310 · 2023: $1,487 · 2024: $1,119 · 2025: $1,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,396.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,282.42 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $1,111.05 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $903.31 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $791.85 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $728.13 | 2019-2022 | |
| Glaxosmithkline, LLC. | $525.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $420.98 | 2019-2025 | Tavneos, Evenity, Prolia |
| Merz North America, INC. | $374.98 | 2023 | Xeomin |
| Sanofi-Aventis U.S. LLC | $371.71 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $358.30 | 2019-2022 | |
| Allergan, INC. | $353.68 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $345.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.03 | 2019-2022 | |
| Si-Bone, INC. | $311.46 | 2025 | |
| Astellas Pharma US INC | $303.11 | 2019-2023 | Veozah |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haoran Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.